文献速递痛风与晶体性关节病

阿那白滞素治疗晶体相关急性发作的疗效与感染风险相关因素

Factors associated with anakinra effectiveness and risk of infection in crystal-related flares.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

这项单中心回顾性观察研究纳入2011年1月至2024年7月因晶体相关疾病急性发作接受阿那白滞素治疗的292例成人患者,评估疗效与安全性。中位治疗3天后92.8%患者有效,糖尿病史和较长病程与治疗失败独立相关,4.5%患者在启动后1个月内发生感染。

要点

  • 阿那白滞素治疗晶体相关急性发作有效率高,中位3天起效。
  • 糖尿病史与较长病程是治疗失败的独立相关因素。
  • 启动后1个月内感染发生率4.5%,未发现独立危险因素。

核心结论

  • 阿那白滞素在晶体相关疾病急性发作中显示良好疗效和总体安全性。

研究设计与样本

  • 单中心、回顾性、观察性研究,纳入2011年1月至2024年7月接受阿那白滞素治疗的成人晶体相关疾病发作患者292例。
  • 晶体相关疾病经滑液晶体或特征性影像学确认,疗效由病历记录的医生整体临床判断回顾性评估。

主要发现

  • 中位治疗3天后92.8%患者观察到阿那白滞素有效。
  • 多因素分析中,较长晶体相关疾病病程(OR 1.11,95%CI 1.03-1.19)和糖尿病史(OR 4.00,95%CI 1.25-14.29)与治疗失败独立相关。
  • 未发现与感染风险独立相关的变量。

关键数值与推荐

  • 治疗失败定义为临床应答不足需升级治疗或症状持续。
  • 不良事件(含感染)收集至阿那白滞素启动后1个月。
  • 较长病程OR 1.11(95%CI 1.03-1.19),糖尿病史OR 4.00(95%CI 1.25-14.29),均为治疗失败相关因素。

临床怎么用

  • 对于晶体相关疾病急性发作,阿那白滞素可作为有效治疗选择,尤其需关注糖尿病史和较长病程患者的治疗失败风险。
  • 用药后1个月内需监测感染,中位发生时间为11天。

局限性

  • 为单中心回顾性观察研究,疗效基于医生整体临床判断回顾性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effectiveness and safety of anakinra in crystal-related disease (CRD) flares, and to identify factors associated with treatment failure and risk of infection. METHODS: We conducted a single-centre, retrospective, observational study including adult patients treated with anakinra for a CRD flare between January 2011 and July 2024. Patients were identified in a hospital clinical data warehouse using an electronic query. CRD was confirmed by the presence of crystals in synovial fluid or by characteristic radiological features. Clinical and biological data were collected through medical record review. Treatment effectiveness was assessed retrospectively based on the treating physician's global clinical judgment documented in medical records. Treatment failure was defined as insufficient clinical response requiring treatment escalation or persistent symptoms. Adverse events, including infections, were collected up to one month after anakinra initiation. Factors associated with treatment failure and infection were explored using univariable and multivariable analyses. RESULTS: A total of 292 patients were included. Effectiveness of anakinra was observed in 92.8% of patients after a median treatment duration of 3 days. In multivariate analysis, longer CRD duration (OR 1.11, 95% CI 1.03-1.19) and a history of diabetes (OR 4.00, 95% CI 1.25-14.29) were independently associated with treatment failure. Thirteen patients (4.5%) developed an infection within one month after anakinra initiation, with a median delay of 11 days. No variable was independently associated with infection risk. CONCLUSION: This large real-life study supports the effectiveness and overall safety of anakinra in the management of acute CRD flares.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Moriot C, Juge PA, Ottaviani S, et al. Factors associated with anakinra effectiveness and risk of infection in crystal-related flares. Rheumatology (Oxford). 2026. PMID: 41926750. doi:10.1093/rheumatology/keag156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。